Regentis Biomaterials (RGNT) CEO details vested options and warrants

Rhea-AI Filing Summary

REGENTIS BIOMATERIALS LTD. director and Chief Executive Officer Ehud Geller filed an initial Form 3 detailing his derivative holdings in the company. He reports fully vested employee stock options to acquire 182,000 shares of common stock at an exercise price of $0.01 per share, expiring on December 5, 2035, and additional fully vested options over 283,533 shares at the same exercise price, expiring on March 20, 2035. He also reports directly held warrants that are currently exercisable to purchase 92,821 ordinary shares at an exercise price of $5.00 per share, with a three-year term ending on December 5, 2028. The filing records these derivative positions but does not report any new purchases or sales.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider GELLER EHUD

Role Chief Executive Officer

Type	Security	Shares	Price	Value
holding	Employee Stock Option (Right to Buy)	--	--	--
holding	Employee Stock Option (Right to Buy)	--	--	--
holding	Warrants to purchase ordinary shares	--	--	--

Holdings After Transaction: Employee Stock Option (Right to Buy) — 182,000 shares (Direct); Warrants to purchase ordinary shares — 92,821 shares (Direct)

Footnotes (1)

1. This option grant is fully vested as of this date. This option grant is fully vested as of this date. The warrants are currently exercisable and have a three year term.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

GELLER EHUD

(Last) (First) (Middle)

C/O REGENTIS BIOMATERIALS LTD.

60 MEDINAT HAYEHUDIM

(Street)

HERZLIYA 4676652

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
REGENTIS BIOMATERIALS LTD. [ RGNT ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	(1)	12/05/2035	Common Stock	182,000	$0.01	D
Employee Stock Option (Right to Buy)	(2)	03/20/2035	Common Stock	283,533	$0.01	D
Warrants to purchase ordinary shares	(3)	12/05/2028	Common Stock	92,821	$5	D

Explanation of Responses:

1. This option grant is fully vested as of this date.

2. This option grant is fully vested as of this date.

3. The warrants are currently exercisable and have a three year term.

	/s/ Ehud Geller	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What insider positions does RGNT CEO Ehud Geller report on this Form 3?

Ehud Geller reports directly held derivative positions, not common shares. He lists fully vested employee stock options over 182,000 and 283,533 common shares at $0.01 exercise prices, plus currently exercisable warrants for 92,821 ordinary shares at $5.00 per share.

Are Ehud Geller’s Regentis (RGNT) stock options already vested?

Yes. The filing notes that both employee stock option grants are fully vested as of the reported date. They cover 182,000 and 283,533 underlying common shares, each with a $0.01 exercise price and expirations in 2035, indicating long-dated, exercisable awards.

What are the key terms of the warrants reported by RGNT’s CEO?

Geller reports warrants to purchase 92,821 ordinary shares of Regentis common stock. These warrants are currently exercisable at an exercise price of $5.00 per share and have a three-year term, expiring on December 5, 2028, according to the footnote disclosure.

Does this RGNT Form 3 show Ehud Geller buying or selling shares?

No. The Form 3 records holdings rather than transactions. The transaction summary shows no buys, sells, exercises, gifts, or tax withholdings, only three holding entries reflecting existing options and warrants positions controlled directly by Geller as of the reporting date.

How many common shares underlie Ehud Geller’s reported RGNT derivatives?

The filing lists three derivative positions over Regentis common stock. They include options on 182,000 shares, options on 283,533 shares, and warrants on 92,821 shares. Each position has its own exercise price and expiration date, providing detailed visibility into his derivative exposure.